GSK vs AMRN
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 04, 2026
GSK
47.3
AI Score
VS
GSK Wins
AMRN
39.9
AI Score
Investment Advisor Scores
AMRN
40score
Recommendation
SELL
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | GSK | AMRN | Winner |
|---|
Relative Price Performance (Last 90 Days)
GSK 1M: +4.6%
· 3M: -5.4%
AMRN 1M: -0.3%
· 3M: -16.4%
Current Technical Phase
GSK
DistributionTrim / tighten stop
Price near a flattening SMA50 (slope -2.2%) with fading momentum, RSI 47
AMRN
NeutralHold
Mixed signals - no dominant trend phase, RSI 46
Fundamentals Snapshot
| Metric | GSK | AMRN |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 9.8 | -200.8 |
| Trailing P/E | 17.1 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | -0.2% |
| Gross Margin | 0.7% | 0.4% |
| Operating Margin | 0.3% | -0.1% |
| EPS | 2.87 | -0.80 |
| Dividend Yield | 0.04% | — |
Frequently Asked Questions
Based on our detailed analysis, GSK is currently the stronger investment candidate based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.